- Home
- FFC vs CGEM Comparison
FFC vs CGEM Comparison
Compare FFC & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFC
- CGEM
- Stock Information
- Founded
- FFC 1983
- CGEM 2016
- Country
- FFC United States
- CGEM United States
- Employees
- FFC N/A
- CGEM N/A
- Industry
- FFC Trusts Except Educational Religious and Charitable
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- FFC Finance
- CGEM Health Care
- Exchange
- FFC Nasdaq
- CGEM Nasdaq
- Market Cap
- FFC 757.4M
- CGEM 730.2M
- IPO Year
- FFC N/A
- CGEM 2021
- Fundamental
- Price
- FFC $16.06
- CGEM $10.42
- Analyst Decision
- FFC
- CGEM Strong Buy
- Analyst Count
- FFC 0
- CGEM 7
- Target Price
- FFC N/A
- CGEM $31.67
- AVG Volume (30 Days)
- FFC 164.1K
- CGEM 580.7K
- Earning Date
- FFC 01-01-0001
- CGEM 03-13-2025
- Dividend Yield
- FFC 6.79%
- CGEM N/A
- EPS Growth
- FFC N/A
- CGEM N/A
- EPS
- FFC N/A
- CGEM N/A
- Revenue
- FFC N/A
- CGEM N/A
- Revenue This Year
- FFC N/A
- CGEM N/A
- Revenue Next Year
- FFC N/A
- CGEM N/A
- P/E Ratio
- FFC N/A
- CGEM N/A
- Revenue Growth
- FFC N/A
- CGEM N/A
- 52 Week Low
- FFC $11.90
- CGEM $9.50
- 52 Week High
- FFC $14.96
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- FFC 62.50
- CGEM 36.51
- Support Level
- FFC $15.55
- CGEM $9.50
- Resistance Level
- FFC $15.88
- CGEM $11.31
- Average True Range (ATR)
- FFC 0.19
- CGEM 0.71
- MACD
- FFC 0.04
- CGEM -0.09
- Stochastic Oscillator
- FFC 97.22
- CGEM 26.38
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.